Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 26, 2020

Pfizer reports safety data of azithromycin in Covid-19 trial

Pfizer has announced positive data for the use of its azithromycin (Zithromax) drug, along with hydroxychloroquine, in a coronavirus (Covid-19) clinical trial performed in France.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Pfizer has announced positive data for the use of its azithromycin (Zithromax) drug, along with hydroxychloroquine, in a coronavirus (Covid-19) clinical trial performed in France.

The trial was conducted to assess anti-malarial drug hydroxychloroquine in 20 patients, six of which were also administered with azithromycin.

Compared with 16 controls, the proportion of participants who achieved virologic cure following six days of treatments was observed to be higher in the 20 patients treated with hydroxychloroquine.

In addition, the rate of cure was highest in people who received hydroxychloroquine and azithromycin.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Pfizer previously assessed azithromycin as an anti-infective alone and also in combination with other therapies, including chloroquine.

A fixed-dose azithromycin and chloroquine combination was specifically evaluated to treat and prevent malaria in Africa. The combination was found to be well-tolerable and non-inferior to mefloquine.

A separate study in pregnant women in sub-Saharan Africa showed that the combination did not meet efficacy endpoints as a preventive treatment for malaria but demonstrated an acceptable safety profile.

Commenting on the data, Pfizer said: “It is important to note that the doses Pfizer has studied with the combination of azithromycin and chloroquine in malaria may have a different safety profile than the recently reported study combining azithromycin with hydroxychloroquine.

“Pfizer would like to highlight these published studies to facilitate further research efforts to study azithromycin in combination with other agents to mitigate Covid-19 disease.”

Earlier this month, Pfizer announced a five-point strategy to fight the outbreak.

Meanwhile, the company has delayed patient enrolment in new and ongoing trials for three weeks to cut the burden on healthcare facilities and doctors amid the spreading Covid-19 pandemic.

The move will not include some studies in patients with life-threatening conditions that have limited or no therapeutic options, noted Reuters.

Eli Lilly also announced plans to delay its clinical trial activities in the wake of the pandemic.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy